Scott Mazza, Director of Pharmacy at ZipHealth and CDRX, offer more context for plan sponsors evaluating these meds as potential additions to benefit plans
For medical emergencies, dial 911 or visit your nearest emergency department immediately
Brighten: Yes, I, [00:20:00] I don't think everybody knows about the dosing and I think when we say micro dosing and then these high doses, I think that might be confusing
Elevate your protocols with a diluent you can trust
this remains investigational and does not represent an approved or established indication Tolerability profile : Whether retatrutide's gastrointestinal side effect burden differs meaningfully from dual agonists cannot be determined without head-to-head comparative data Retatrutide is not approved in the UK
This highlights the need to consider the risks and benefits of these medications